PANDAR

Summary

PANDAR (promoter of CDKN1A antisense DNA damage activated RNA, HGNC:44048) is a long non-coding RNA gene on chromosome 6p21.2.

This gene produces a non-coding RNA that is thought to regulate the response to DNA damage. This gene is induced by tumor protein p53 and interacts with and modulates the activity of a transcription factor that induce pro-apoptotic genes. Deregulation of this gene is associated with cancer progression.

Source: NCBI Gene 101154753 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:44048
Approved symbol	PANDAR
Name	promoter of CDKN1A antisense DNA damage activated RNA
Location	6p21.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	PANDA
Ensembl gene	ENSG00000281450
Ensembl biotype	lncRNA
OMIM	617179
Entrez	101154753
RNAcentral	URS0000524E5C — lncRNA, 1506 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 lncRNA

ENST00000629595

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000629595 — 1 exons

Exon	Start	End
ENSE00003773816	36673621	36675126

Expression profiles

Bgee: expression breadth broad, 30 present calls, max score 58.98.

Top tissues by expression

30 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	58.98	silver quality
liver	UBERON:0002107	57.58	silver quality
prefrontal cortex	UBERON:0000451	53.12	silver quality
islet of Langerhans	UBERON:0000006	52.43	silver quality
blood	UBERON:0000178	49.47	gold quality
brain	UBERON:0000955	49.35	silver quality
heart	UBERON:0000948	47.38	silver quality
muscle of leg	UBERON:0001383	47.11	silver quality
multicellular organism	UBERON:0000468	46.53	gold quality
gastrocnemius	UBERON:0001388	45.88	silver quality
spleen	UBERON:0002106	45.85	gold quality
gall bladder	UBERON:0002110	45.85	silver quality
tibial artery	UBERON:0007610	45.72	gold quality
small intestine	UBERON:0002108	45.44	silver quality
adrenal gland	UBERON:0002369	43.95	silver quality
heart left ventricle	UBERON:0002084	43.70	silver quality
vermiform appendix	UBERON:0001154	43.22	silver quality
subcutaneous adipose tissue	UBERON:0002190	41.50	silver quality
ascending aorta	UBERON:0001496	41.28	silver quality
omental fat pad	UBERON:0010414	41.17	silver quality
skin of leg	UBERON:0001511	39.75	silver quality
skin of abdomen	UBERON:0001416	39.64	silver quality
thoracic aorta	UBERON:0001515	38.96	silver quality
prostate gland	UBERON:0002367	38.91	silver quality
left adrenal gland cortex	UBERON:0035825	38.69	silver quality
thoracic mammary gland	UBERON:0005200	37.79	silver quality
esophagus mucosa	UBERON:0002469	37.22	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	37.08	silver quality
lower esophagus muscularis layer	UBERON:0035833	36.28	silver quality
caudate nucleus	UBERON:0001873	36.24	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.10

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 21)

• The aim of this study was to determine the expression pattern and clinical value of PANDAR, a novel lncRNA, in hepatocellular carcinoma. (PMID:26054684)
• PANDAR may be a potential novel biomarker that predicts prognosis in gastric cancer. (PMID:26898439)
• results suggest that PANDA stabilizes p53 protein in response to DNA damage, and provide new insight into the regulatory mechanisms of p53 (PMID:27069137)
• Study shows that LncRNA PANDAR was up-regulated in bladder cancer tissues and positively correlated with higher histological grade and advanced TNM stage. Its silencing inhibited cell proliferation and its overexpression promoted cell proliferation suggesting that PANDAR plays oncogenic roles in bladder cancer . (PMID:27206339)
• Colorectal cancer patients with high PANDAR expression level had poorer overall survival than those with low PANDAR expression. (PMID:27629879)
• Suggest that PANDA promotes G1-S transition by repressing p18 transcription, and thus promotes U2OS cell proliferation. (PMID:28011477)
• Our results suggest that high expression of PANDAR was involved in colorectal cancer ( CRC) progression and could act as an independent biomarker for prognosis of CRC patients (PMID:28106228)
• PANDAR was significantly upregulated in clear cell renal cell carcinoma tissues compared to corresponding normal tissues. PANDAR could modulate the antiapoptotic proteins Bcl-2 and Mcl-1, as well as the PI3K/Akt/mTOR pathway. (PMID:28545465)
• PANDA repressed transcriptional activity of senescence associated inflammatory factor IL8, which leaded to inhibition of cellular senescence. (PMID:28646235)
• PANDAR was aberrantly overexpressed in Pancreatic ductal adenocarcinoma tissues and cell lines (PMID:28886528)
• High PANDAR expression correlated with poor overall survial in cancer patients. (Meta-analysis) (PMID:29066211)
• The knockdown of PANDAR expression significantly inhibited the proliferation of cervical cancer cells. (PMID:29131264)
• PANDAR controlled the transcription of the CDKN1A gene by competitively binding with p53 protein. (PMID:29416011)
• Authors observed that overexpression of PANDAR leads to a reduced level of the short pro-apoptotic BCL-X splice variant (BCL-XS) which is regulated by PTBP1. Simultaneous overexpression of PTBP1 was able to rescue this effect. (PMID:29434205)
• This study demonstrated that the PANDAR significantly over-expressed in MS patients compared with healthy subjects. (PMID:30114626)
• The cisplatin-induced long non-coding RNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. (PMID:30375398)
• Over-expression of LncRNA PANDAR was indicared to be effectively predictive of cancer progression [Meta-analysis]. (PMID:30775883)
• we showed that lncRNA PANDAR expression was upregulated in breast cancer tissues and cells. Furthermore, we demonstrated that lncRNA PANDAR knockdown inhibited cell proliferation, cell invasion ability and EMT signaling pathway in breast cancer. (PMID:31104011)
• Knockdown of lincRNA PADNA promotes bupivacaine-induced neurotoxicity by miR-194/FBXW7 axis. (PMID:32791990)
• The long non-coding RNA PANDAR regulates cell proliferation and epithelial-to-mesenchymal transition in glioma. (PMID:36073766)
• Hypomethylation at PANDAR promoter progressively induces senescence in adipocyte precursor cells in subjects with obesity and type 2 diabetes. (PMID:39373976)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.